Special Report

Wilmer Cutler Pickering Hale and Dorr LLP, 399 Park Avenue, New York, NY 10022, USA.

Email the corresponding author at jane.love@wilmerhale.com

Jane M Love

† Author for correspondence

Wilmer Cutler Pickering Hale and Dorr LLP, 399 Park Avenue, New York, NY 10022, USA.

Search for more papers by this author

Email the corresponding author at jane.love@wilmerhale.com

Published Online:15 Jul 2010https://doi.org/10.2217/rme.10.43

View article

Abstract

Human induced pluripotent stem (iPS) cells and human embryonic stem cells are cells that have the ability to differentiate into a variety of cell types. Embryonic stem cells are derived from human embryos; however, by contrast, human iPS cells can be obtained from somatic cells that have undergone a process of ‘reprogramming’ via genetic manipulation such that they develop pluripotency. Since iPS cells are not derived from human embryos, they are a less complicated source of human pluripotent cells and are considered valuable research tools and potentially useful in therapeutic applications in regenerative medicine. Worldwide, there are only three issued patents concerning iPS cells. Therefore, the patent landscape in this field is largely undefined. This article provides an overview of the issued patents as well as the pending published patent applications in the field.

Keywords:

Papers of special note have been highlighted as: ▪ of interest

Bibliography

1 Thomson JA, Itskovitz-Eldor J, Shapiro SS et al.: Embryonic stem cell lines derived from human blastocysts. Science282(5391),1145–1147 (1998).
Medline CASGoogle Scholar
2 Shamblott MJ, Axelman J, Wang S et al.: Derivation of pluripotent stem cells from cultured human primordial germ cells. Proc. Natl Acad. Sci. USA95(23),13726–13731 (1998).
Medline CASGoogle Scholar
3 Gearhart J: A decade of stem-cell research. An interview with John Gearhart, Director of the Institute for Regenerative Medicine at the University of Pennsylvania, USA. Interview by Howard Wolinsky. EMBO Rep.10(1),12–16 (2009).
MedlineGoogle Scholar
4 Takahashi K, Tanabe K, Ohnuki M et al.: Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell131(5),861–872 (2007).
Medline CASGoogle Scholar
5 Yu J, Vodyanik MA, Smuga-Otto K et al.: Induced pluripotent stem cell lines derived from human somatic cells. Science318(5858),1917–1920 (2007).
Medline CASGoogle Scholar
6 Kang L, Wang J, Zhang Y, Kou Z, Gao S: IPS cells can support full-term development of tetraploid blastocyst-complemented embryos. Cell Stem Cell5(2),135–138 (2009).
Medline CASGoogle Scholar
7 Stadtfeld M, Nagaya M, Utikal J, Weir G, Hochedlinger K: Induced pluripotent stem cells generated without viral integration. Science322(5903),945–949 (2008).
Medline CASGoogle Scholar
8 Yu J, Hu K, Smuga-Otto K et al.: Human induced pluripotent stem cells free of vector and transgene sequences. Science324(5928),797–801 (2009).
Medline CASGoogle Scholar
9 Zhou H, Wu S, Joo JY et al.: Generation of induced pluripotent stem cells using recombinant proteins. Cell Stem Cell4(5),381–384 (2009).
Medline CASGoogle Scholar
10 Huangfu D, Osafune K, Maehr R et al.: Induction of pluripotent stem cells from primary human fibroblasts with only Oct4 and Sox2. Nat. Biotechnol.26(11),1269–1275 (2008).
Medline CASGoogle Scholar
11 Ichida JK, Blanchard J, Lam K et al.: A small-molecule inhibitor of TGF-β signaling replaces Sox2 in reprogramming by inducing Nanog. Cell Stem Cell5(5),491–503 (2009).
Medline CASGoogle Scholar
12 Webb S: The gold rush for induced pluripotent stem cells. Nat. Biotechnol.27(11),977–979 (2009).
Medline CASGoogle Scholar
13 United States Code (USC). Title 35: Patent Statute.
Google Scholar
14 European Patent Office: Enlarged Board of Appeal of the European Patent Office decision. G0002/06, 26 November 2008.
Google Scholar
15 Bilski v. Doll, 545 F.3d 943 (Fed.Cir. 2008), petition for writ of certiorari to the US Court of Appeals for the Federal Circuit granted, 129 S.Ct. 2735 (US 2009).
Google Scholar
16 Ass’n for Molecular Pathology et al. v. US PTO et al., 2010 WL 1233416 (S.D.N.Y. 2010).▪ Important case as it found patent claims to isolated genes to be invalid.
Google Scholar
17 Doi A, Park IH, Wen B et al.: Differential methylation of tissue- and cancer-specific CpG island shores distinguishes human induced pluripotent stem cells, embryonic stem cells and fibroblasts. Nat. Genet.41(12),1350–1353 (2009).
Medline CASGoogle Scholar
18 Chin MH, Mason MJ, Xie W et al.: Induced pluripotent stem cells and embryonic stem cells are distinguished by gene expression signatures. Cell Stem Cell5(1),111–123 (2009).
Medline CASGoogle Scholar
19 Baker M: Stem cells: fast and furious. Nature458(7241),962–965 (2009).
Medline CASGoogle Scholar
20 SmithKline Beecham Corp. v. Apotex Corp., 439 F.3d 1312, 1319 (Fed.Cir. 2006).
Google Scholar
21 Abbott Laboratories v. Sandoz, Inc., 566 F.3d 1282, 1293 (Fed.Cir. 2009).
Google Scholar
22 Hwang WS, Ryu YJ, Park JH et al.: Evidence of a pluripotent human embryonic stem cell line derived from a cloned blastocyst. Science303(5664),1669–1674 (2004).
Medline CASGoogle Scholar
23 Kennedy D: Editorial retraction. Science311(5759),335 (2006).
Medline CASGoogle Scholar
24 Ariad Pharmaceuticals, Inc. v. Eli Lilly and Co., 560 F.3d 1366 (Fed.Cir. 2009), petition for reh’g granted, 332 Fed.Appx. 636 (Fed.Cir. 2009).
Google Scholar
25 Park IH, Zhao R, West JA et al.: Reprogramming of human somatic cells to pluripotency with defined factors. Nature451(7175),141–146 (2008).
Medline CASGoogle Scholar
26 Hanna J, Markoulaki S, Schorderet P et al.: Direct reprogramming of terminally differentiated mature B lymphocytes to pluripotency. Cell133(2),250–264 (2008).
Medline CASGoogle Scholar
101 Wisconsin Alumni Research Foundation: US5843780C1 (2008).
Google Scholar
102 Wisconsin Alumni Research Foundation: US6200806C1 (2008).
Google Scholar
103 Jaenisch R, Hochedlinger K: US7682828 (2010).▪ Important patent as it is one of only three issued patents with claims regarding induced pluripotent stem (iPS) cells.
Google Scholar
104 Sakurada K, Masaki H, Ishikawa T, Takahashi S: GB2450603 (2010).▪ Important patent as it is one of only three issued patents with claims regarding iPS cells.
Google Scholar
105 iZumi Bio, Inc.: WO2009006930 (2009).
Google Scholar
106 iZumi Bio, Inc.: WO2009006997 (2009).
Google Scholar
107 iZumi Bio, Inc.: WO2009007852 (2009).
Google Scholar
108 Sakurada K, Masaki H, Ishikawa T, Takahashi S: US20090191159 (2009).
Google Scholar
109 Sakurada K: US20090299763 (2009).
Google Scholar
110 Sakurada K, Masaki H, Ishikawa T, Takahashi S: US20090304646 (2009).
Google Scholar
111 Sakurada K, Seidenman KJ: US20090324559 (2009).
Google Scholar
112 Yamanaka S: JP04183742 (2008).▪ Important patent as it is one of only three issued patents with claims regarding iPS cells.
Google Scholar
113 Yamanaka S: US20090068742 (2009).
Google Scholar
114 Yamanaka S, Takahashi K, Nakagawa M: US20090047263 (2009).
Google Scholar
115 Yamanaka S, Takahashi K; Nakagawa M: US20090227032 (2009).
Google Scholar
116 Yamanaka S, Koyanagi M: US20090246875 (2009).
Google Scholar
117 Thomson J, Yu J: US20080233610; WO2008118820 (2008).
Google Scholar
118 Mack A, Thomson J: US20100003757 (2010).
Google Scholar
119 Helmholtz Zentrum München – Deutsches Forschungszentrum für Gesundheit und Umwelt (GMBH): WO2009115295 (2009).
Google Scholar
120 Nevada Cancer Institute: WO2009092042 (2009).
Google Scholar
121 The Scripps Research Institute: WO2009117439 (2009).
Google Scholar
122 President and Fellows of Harvard College: WO2009102983 (2009).
Google Scholar
123 Mirae Biotech Co., Ltd.: WO2009096614 (2009).
Google Scholar
124 Children’s Medical Center Corporation: WO2009061442 (2009).
Google Scholar
125 Whitehead Institute for Biomedical Research: WO2009032194 (2009).
Google Scholar
126 Whitehead Institute for Biomedical Research: WO2008124133 (2008).
Google Scholar
127 The General Hospital Corporation: WO2008151058 (2008).
Google Scholar
128 Primegen Biotech LLC: WO2009032456 (2009).
Google Scholar
129 Jonannes Gutenberg-Universitat Mainz: WO2009077134 (2009).
Google Scholar
130 Lin S, Ying S, Wu DTs: US20080293143 (2008).
Google Scholar
131 Wisconsin Alumni Research Foundation: US7029913 (2006).
Google Scholar
201 Executive Order of March 9, 2009: Removing barriers to responsible scientific research involving human stem cells, 74 Federal Register 10667 11 March (2009) www.archives.gov/federal-register/executive-orders/2009-obama.html
Google Scholar
202 NIH Guidelines for Human Stem Cells Research, 2009 http://stemcells.nih.gov/policy/2009guidelines.htm
Google Scholar
203 Section 509, Omnibus Appropriation Act, 2010, HR3288.ENR. Pub. L. 111–117, December 16, 2009; known as the Dickey-Wicker Amendment, re-enacted annually by Congress, original rider can be found in Section 128 of PL 104–199, 110 Stat. 26, 34 (1996) http://thomas.loc.gov/cgi-bin/bdquery/D?d111:3:./temp/∼bdjTyD::|/home/LegislativeData.php|
Google Scholar
204 Stein R: US set to fund more stem cell study www.washingtonpost.com/wp-dyn/content/article/2009/12/02/AR2009120201955.html
Google Scholar

Vol. 5, No. 4

Metrics

Downloaded 424 times

History

Published online 15 July 2010

Published in print July 2010

Information

Keywords

Financial & competing interests disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

PDF download

Human induced pluripotent stem cells: a review of the US patent landscape

Abstract

Bibliography